Early trials are underway with several demonstrating safety or clinical responses in cancer patients with RNAi therapies targeting mRNAs that encode protein kinase N3 (PKN3) Polo kinase 1 (PLK1), vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP), the K-Ras G12D mutant, and the M2 subunit of ribonucleotide reductase (RRM2) [3]. The gene discussed is VEGFA; the disease is cancer.